

# Yong Lv

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8495514/publications.pdf>

Version: 2024-02-01

36  
papers

1,298  
citations

393982

19  
h-index

414034

32  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1278  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. <i>Journal of Hepatology</i> , 2019, 70, 893-903.	1.8	153
2	Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 587-598.	3.7	147
3	Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. <i>Gut</i> , 2018, 67, 2156-2168.	6.1	132
4	Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. <i>Journal of Hepatology</i> , 2017, 67, 508-516.	1.8	131
5	Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study. <i>Gut</i> , 2019, 68, 1297-1310.	6.1	102
6	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	0.6	97
7	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <i>Journal of Hepatology</i> , 2021, 74, 1362-1372.	1.8	74
8	Hepatic Hydrothorax. <i>Annals of Hepatology</i> , 2018, 17, 33-46.	0.6	44
9	Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 686-697.	3.7	37
10	Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial. <i>Hepatology</i> , 2022, 76, 676-688.	3.6	35
11	Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 1315-1323.	0.4	33
12	Hepatopulmonary Syndrome. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1914-1923.	1.1	32
13	Risk Stratification Based on Chronic Liver Failure Consortium Acute Decompensation Score in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding. <i>Hepatology</i> , 2021, 73, 1478-1493.	3.6	31
14	Endovascular Management of Budd-Chiari Syndrome with Inferior Vena Cava Thrombosis: A 14-Year Single-Center Retrospective Report of 55 Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1592-1603.	0.2	25
15	Transjugular Intrahepatic Portosystemic Shunt for Extrahepatic Portal Venous Obstruction in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 62, 233-241.	0.9	25
16	Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. <i>Radiology</i> , 2017, 285, 999-1010.	3.6	25
17	TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 926-939.	1.9	24
18	Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 148-153.e2.	0.2	24

#	ARTICLE	IF	CITATIONS
19	Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 736-746.	3.7	24
20	Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells. <i>Investigational New Drugs</i> , 2020, 38, 1247-1256.	1.2	18
21	Abnormal Liver Function Tests Were Associated With Adverse Clinical Outcomes: An Observational Cohort Study of 2,912 Patients With COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 639855.	1.2	16
22	Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study. <i>Liver Cancer</i> , 2022, 11, 368-382.	4.2	10
23	Hand-foot-skin reaction of grade 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC. <i>Investigational New Drugs</i> , 2019, 37, 401-414.	1.2	9
24	Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. <i>Liver Cancer</i> , 2020, 9, 308-325.	4.2	9
25	Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS. <i>JHEP Reports</i> , 2022, 4, 100448.	2.6	7
26	Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China. <i>Liver International</i> , 2023, 43, 18-33.	1.9	7
27	Portopulmonary hypertension. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 795-806.	0.6	6
28	Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1049-1056.	1.4	6
29	Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1547-1555.	0.8	5
30	Spleen Stiffness Performance in the Noninvasive Assessment of Gastroesophageal Varices after Transjugular Intrahepatic Portosystemic Shunts. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	4
31	Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: Not Only Recanalize the Portal Vein. <i>Gastroenterology</i> , 2018, 154, 758-759.	0.6	3
32	Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. <i>European Radiology</i> , 2022, 32, 5799-5810.	2.3	3
33	Use of 8-mm Covered TIPS: Is Losses without Gains the End of the Story?. <i>Radiology</i> , 2017, 284, 604-604.	3.6	0
34	REPLY:. <i>Hepatology</i> , 2021, 74, 2919-2919.	3.6	0
35	Response to Jindal and Mukund. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, 2306.	0.2	0
36	Correction to: Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 200-200.	0.2	0